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Abstract 
We describe a case of acute liver injury and migratory arthralgia in a patient receiving bicalu-
tamide treatment for prostate cancer. A 67-year-old male with metastatic prostate cancer pre-
sented with a 6-day history of migratory arthralgia. He had been undergoing treatment with 
bicalutamide for 4 months; 3 weeks prior to symptom appearance the bicalutamide dose had 
been increased. He had no other symptoms. Liver tests and inflammatory markers were mark-
edly elevated. Serology for hepatitis viruses A, B, and C, CMV, and EBV and autoimmune causes 
were all negative, and an ultrasound of the upper abdomen was normal. There was no history 
of blood transfusion, intravenous drug abuse, or alcohol abuse. Due to the suspicion of a drug-
induced symptomatology, bicalutamide was discontinued and the patient started on 30 mg 
prednisolone daily. Three weeks later he was symptom free and after 6 weeks his liver tests 
were almost normal. The Roussel Uclaf Causality Assessment Method (RUCAM) suggested a 
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high probability of liver injury. Bicalutamide has very rarely been reported as a causative agent 
for liver injury and to our knowledge never for migratory polyarthralgia. The migratory poly-
arthralgia was attributed to bicalutamide due to the absence of other etiological factors and 
the disappearance of symptoms after discontinuation of the drug. To our knowledge, this is 
the first published case report of migratory arthralgia and concomitant liver injury attributed 
to bicalutamide. © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Prostate cancer is an important health care issue and is the second leading cause of cancer 
in men worldwide. Most cases of prostate cancers are now being diagnosed at an early disease 
stage and in younger men, due in part to the widespread measurements of serum prostate-
specific antigen [1]. Management of the prostate cancer confined to the prostate gland in-
cludes watchful waiting, radical prostatectomy, radiation therapy, or hormonal therapy [2]. 
Once the cancer extends beyond the prostate gland (stages T3–4, N+, M+) hormonal therapy 
is the mainstay of treatment [1]. The most commonly used agents are medical castration with 
luteinizing hormone-releasing hormone agonists, maximum androgen blockade, and anti-
androgen monotherapy including bicalutamide [1]. 
We describe a case of an acute liver injury and migratory arthralgia in a patient receiving 
bicalutamide treatment for prostate cancer without an underlying arthritic or hepatic disease. 
To our knowledge, this is the first published case report of migratory arthralgia and concom-
itant liver injury attributed to bicalutamide. 
Case Report 
A 67-year-old Caucasian male with a history of hypertension and kidney stones was diag-
nosed with locally advanced prostatic cancer. The cancer was in Gleason scale 4 + 3 adenocar-
cinoma (cT3bN0M0) with a prostate-specific antigen level of 46 ng/mL (normal <4 ng/mL). 
His only other medication included enalapril (ACE inhibitor) and angelica root (Angelica  
archangelica), a dietary supplement, both of which he had been taking for a few years. He was 
started on treatment with 50 mg ×1 bicalutamide (a nonsteroidal antiandrogen), goserelin (a 
luteinizing hormone-releasing hormone agonist), 3.6 mg s.c. every 28 days, and radiation ther-
apy which he tolerated well. Four months after starting bicalutamide (125 days) the dose was 
increased to 150 mg ×1. Twenty-three days later he developed an intensive pain in the left 
shoulder that later moved to the right shoulder, leaving the left shoulder symptom free, fol-
lowed by migration to the left hip and right hand, ending only with jaw pain. The pain became 
so severe that he sought assistance in the emergency room. He had no fever, respiratory symp-
toms, or gastrointestinal symptoms accompanying the arthralgia. Both liver tests and inflam-
matory markers were found to be elevated with alkaline phosphatase 468 U/L (normal <105 
U/L), alanine aminotransferase 263 U/L (normal <70 U/L), CRP 187 mg/L (normal <3 mg/L), 
and an erythrocyte sedimentation rate of 73 mm/h (Table 1). An ultrasound of the upper ab-
domen showed no pathological changes in the liver or biliary tree. Hepatitis serology against 
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hepatitis A, B, and C were negative as were tests for immunoglobulin M antibodies to EBV and 
CMV. Furthermore, antinuclear, anti-cyclic citrullinated peptide antibodies and rheumatoid 
factor testing were also negative. There was no history of blood transfusion, intravenous drug 
abuse, or alcohol abuse. Due to the suspicion of a drug-induced symptomatology, bicalutamide 
was discontinued after a week of migratory arthralgia symptoms. The patient was started on 
prednisolone 30 mg per day to treat the arthralgia. He continued on both his enalapril and 
dietary supplement (see above) during the course and after the reaction. 
His symptoms gradually decreased, being pain free 3 weeks later. Six weeks later his liver 
tests were almost normal, except for a slightly elevated alkaline phosphatase (Table 1), and 
the patient remained pain free. According to the Roussel Uclaf Causality Assessment Method 
(RUCAM) [2] the liver injury was highly probable. 
Discussion 
Monotherapy with bicalutamide, an orally active nonsteroidal antiandrogen, is an attrac-
tive alternative in the treatment of prostate cancer as it does not suppress testosterone pro-
duction, offering potential advantages to castration [1]. It inhibits the growth of prostate tu-
mors by antagonizing the action of androgens at the receptor level of both the testis and ad-
renal gland [1]. Bicalutamide is readily absorbed with a linear steady-state concentration with 
a dose over 10–50 mg [1]. If a higher dose is used, the steady-state increase is slightly less than 
dose proportional [3]. It is cleared by both phase I and phase II hepatic metabolism with oxi-
dation and glucuronidation, and eliminated both through bile and by the kidney [3]. The phar-
macokinetics of bicalutamide are not affected by age, renal function, or mild hepatic impair-
ment [3]. The most commonly reported side effects of bicalutamide are gynecomastia, masti-
tis, and hot flushes [3]. Liver injury has very rarely been reported in association with the use 
of bicalutamide, although it has been on the market for more than 20 years [1, 4]. According 
to a recent review only 3 cases of liver injury have been published that were convincingly 
related to the use of the drug [4–7]. Another case was reported but not found to fulfill the 
causality assessment criteria for a possible relationship [4, 8]. Since then 2 cases have been 
reported [9, 10]. In Table 2, all cases reported and found to have at least a possible causal 
relationship are illustrated in terms of demographics, type of liver injury, and outcome. The 
majority of the patients presented in the case reports (Table 2) were similar in age, had no 
prior history of liver disease, and were previously healthy. All of the patients survived except 
for one who died of multiorgan failure after 4 days of bicalutamide treatment [6]. 
Migratory polyarthralgia can be seen in various conditions including reactive arthritis, 
rheumatic fever, or crystalline arthropathies [11–14]. Cases have also been reported on mi-
gratory polyarthralgias as a paraneoplastic phenomenon such as carcinomatous polyarthritis, 
which is a diagnosis of exclusion [12]. Several medications have been reported as causative 
agents for migratory polyarthritis including clopidogrel and propylthiouracil [11, 13]. 
The migratory polyarthralgia was attributed to bicalutamide because of the absence of 
other etiological factors and the disappearance of symptoms after discontinuation of the drug. 
The reaction appeared approximately 3 weeks after the dose of bicalutamide was increased. 
Interestingly, idiosyncratic liver injury has been found to be dose dependent [15].  
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Bicalutamide is commonly used in the treatment of prostate cancer and seems to be bet-
ter tolerated than other antiandrogens. This case report underlines the possible hepatic com-
plications associated with bicalutamide but also draws attention to the other possible side 
effects such as the migratory arthralgia seen in our patient. To our knowledge, this is the first 
presented case where migratory polyarthralgia with concomitant liver injury has been asso-
ciated with bicalutamide. 
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Table 1. Results of laboratory tests at onset and follow-up 
      
      








Bilirubin, μmol/L CRP, mg/L 
 
      
      
Admission 468 107 225 11 187 
Day 3 462 081 167 07 108 
Day 17 184 037 072 – – 
Day 46 112 022 029 07 – 
       
       
ALP, alkaline phosphatase (normal <105 U/L); AST, aspartate aminotransferase (normal <31 U/L); ALT, 
alanine aminotransferase (normal <70 U/L); bilirubin (normal <25 μmol/L); CRP, C-reactive protein 





Table 2. Cases reported in the literature of bicalutamide-induced liver injury 
      
      
Reference Age, 
years 
Dose Duration of  
treatment 
Type of  
injury 
Outcome 
      
      
Dawson et al. [5] 60 050 mg 002 days HC survived 
O’Bryant et al. [6] 59 – 004 days HC death 
Yun et al. [9] 62 100 mg 133 days  HC survived 
Hussain et al. [10] 81 150 mg 021 days  mixed  survived 
Current report  67 150 mg 023 days mixed survived 
      
      
HC, hepatocellular liver injury. 
      
      
 
 
 
